🇺🇸 FDA
Pipeline program

Rivaroxaban 2.5 Mg Oral Tablet

0040139

Phase 3 small_molecule completed

Quick answer

Rivaroxaban 2.5 Mg Oral Tablet for Chronic Kidney Diseases is a Phase 3 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
The George Institute
Indication
Chronic Kidney Diseases
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials